Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 4Completed 4Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Renal Cell 5Neoplasm Metastasis 3Relapsed Pediatric Solid Tumor 1NSCLC 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Biliary Tract Neoplasms 1

Interventions

Carboplatin 84Cisplatin 79Pemetrexed 72Docetaxel 62Drug Therapy 44Gemcitabine 43Erlotinib Hydrochloride 42Gefitinib 38Radiotherapy 36Paclitaxel 36pembrolizumab 31Bevacizumab 29icotinib 28osimertinib 27anlotinib 26Nivolumab 26camrelizumab 23Vinorelbine 23Radiosurgery 20aumolertinib 18atezolizumab 17sintilimab 16apatinib 16Endostatins 16endostar protein 15durvalumab 14Surgical Procedures, Operative 13Immunotherapy 13Immune Checkpoint Inhibitors 12Blood Specimen Collection 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Non-Small-Cell Lung × Axitinib × Clear all
NCT04459663 2020-07-07

JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Sun Yat-sen University

Phase 2 Unknown
50 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡